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Cross-sectional and longitudinal studies exploring clinical, functional, and biological 
correlates of major depressive disorder are frequent. In this type of research, depres-
sion is most commonly defined as a categorical diagnosis based on studies using 
diagnostic instruments. Given the phenotypic and biological heterogeneity of depres-
sion, we chose to focus the phenotypic assessments on three cognitive dimensions 
of depression including (a) cognitive performance, (b) emotion processing, and (c) 
social cognitive functioning. Hence, the overall aim of the study is to investigate the 
long-term clinical course of these cognitive dimensions in depression and its functional 
(psychosocial) correlates. We also aim to identify biological “genomic” correlates of 
these three cognitive dimensions of depression. To address the above overall aim, we 
created the Cognition and Mood Study (CoFaMS) with the key objective to investigate 
the clinical, functional, and biological correlates of cognitive dimensions of depression 
by employing a prospective study design and including a healthy control group. The 
study commenced in April 2015, including patients with a primary diagnosis of a 
major depressive episode of major depressive disorder or bipolar disorder accord-
ing to DSM-IV-TR criteria. The assessments cover the three cognitive dimensions of 
depression (cognitive performance, emotion processing, and social cognition), cog-
nitive function screening instrument, plus functional scales to assess general, work 
place, and psychosocial function, depression symptom scales, and clinical course of 
illness. Blood is collected for comprehensive genomic discovery analyses of biological 
correlates of cognitive dimensions of depression. The CoFaM-Study represents an 
innovative approach focusing on cognitive dimensions of depression and its functional 
and biological “genomic” correlates. The CoFaMS team welcomes collaborations with 
both national and international researchers.
Keywords: depression, cognitive dimensions, cognitive function, emotion processing, social cognition, biological 
correlates, genomic biomarkers
2Baune and Air The Cognition and Function Study – COFAMS
Frontiers in Psychiatry | www.frontiersin.org August 2016 | Volume 7 | Article 150
introduCtion
The lifetime prevalence of 15% for major depressive disorder 
(MDD) within the general population (1) is among the highest 
among all mental disorders. MDD is also one of the leading 
causes of disability and has been estimated to affect 300 million 
people worldwide (2, 3) and is associated with significant medi-
cal and psychosocial morbidity (4–7). Apart from symptoms of 
impaired mood, major depressive disorder is characterized by 
additional emotional, psychological, behavioral, physical, and 
cognitive symptoms, such as neuropsychological dysfunction 
(8, 9). According to the Diagnostics and Statistical Manual of 
Mental Disorders, Fifth Edition (DSM-5) (10), and the International 
Classification of Diseases (ICD-10) (11), cognitive symptoms 
of MDD are characterized by reduced concentration, memory 
deficits, and impaired decision-making processes. Cognitive 
dysfunction is not necessarily a symptom of aging with depres-
sion, but a symptom that may occur frequently across various 
cognitive domains in patients with first episode of depression and 
in young MDD patients (15–25 years of age) (12), in depression 
across all age groups, and during acute and remitted stages of the 
disorder (9).
Specifically, numerous clinical cross-sectional studies have 
established that a range of cognitive symptoms occur frequently 
during the acute state of depression (9). Patients with acute depres-
sion show deficits in various domains such as, but not limited to, 
executive functioning (13–19), audio–verbal functioning (20), 
memory (21, 22), attention (23), attentional set-shifting (24, 25), 
visuo-spatial processing, and psychomotor speed (26). A recently 
published meta-analysis confirmed significant moderate cogni-
tive deficits in the domains of executive function, memory, and 
attention in patients with depression when compared to controls 
(27). Additionally, significant correlations between depression 
severity and cognitive performance were found in the domains of 
episodic memory, executive function, and processing speed but 
not for semantic memory or visuo-spatial memory (28).
However, cognitive impairment may not only affect the indi-
vidual’s ability to function during acute episodes of the illness, as 
a large body of literature now suggests that cognitive dysfunction 
may continue into and after remission (6, 29, 30). As shown in a 
meta-analysis, significant moderate deficits in executive function 
and attention were found to persist in patients whose depressive 
symptoms had remitted, indicating that cognitive impairment 
occurs separately from episodes of depression (27).
In addition to the cognitive deficits during acute and remitted 
stages of major depression, deficits in psychosocial and overall 
functioning in MDD are well recognized and of clinical impor-
tance. A prospective study found that patients with MDD or 
bipolar depressive episodes had moderate to severe impairments 
in work and home functioning as well as mildly to moderately 
impaired relational functioning (31). While evidence on the 
direct relationship between cognitive dysfunction and general 
functioning is emerging, some first evidence suggests that per-
sistent cognitive deficits in depression may play an important 
role in patients’ ability to fully recover functionally over time 
(29, 32). If patients fail to return to work, poor cognitive function 
may be part of this failure as indicated by a study that showed 
that only cognitively recovered patients were able to return 
to work (6). Furthermore, a preliminary study suggests that 
deficits in executive functioning exert a mediating effect on the 
relationship between depression and impaired activities of daily 
living (33). A recently published systematic review confirms the 
relevance of cognitive function in day-to-day functional activi-
ties in MDD (34).
Overall, the implications of poor cognitive function are far 
reaching. Research suggests that MDD patients with neuropsy-
chological deficits tend to be less compliant with antidepressant 
treatment (35) and show an increased risk for suicide (36), both 
of which highlight the clinical importance of neuropsychological 
deficits in depression. In addition to these clinically relevant cog-
nitive deficits in MDD, other cognitive dimensions of depression, 
such as emotion processing and social cognitive functioning, 
can be delineated. These dimensions have long been considered 
at the core of depressive symptoms, as they can affect not only 
how patients feel about themselves and others but also how they 
function on a daily basis and at work. Emotional processing 
distortions in MDD, namely negative attention bias to sad facial 
expressions (37) and oversensitivity to negative feedback (38), 
are key clinical features of depression, which may be present 
in acute and remitted MDD. Similarly, social cognition, which 
is the ability to identify, perceive, and interpret socially relevant 
information in relation to oneself and to others, is an important 
skill that plays a significant role in successful interpersonal and 
day-to-day functioning. The difficulties with social interaction 
observed in major depressive disorder may, at least in part, be 
due to an altered ability to correctly interpret emotional stimuli 
and mental states (37) that seem to persist even in remission of 
MDD, if not responding to intervention.
These cognitive dimensions of depression inherit a number of 
questions that are clinically important and remain unresolved, 
such as (A) the longitudinal course of cognitive deficits in MDD, 
(B) the relationship between cognitive deficits and general 
functioning, and (C) the question how social cognitive deficits 
relate to cognitive function deficits in domains, such as memory, 
attention, and executive function. To address these questions 
in more depth will help provide an understanding as to the 
clinical course and etiology of depression, identifying treatment 
targets of depression more clearly, and will contribute to clinical 
prevention.
Despite significant advances in the elucidating the neuro-
biology of depression in recent years, the neurobiological cor-
relates of cognition also warrant further investigation. Since it 
is undisputed that psychological processes, including cognitive 
function, have a neuronal representation, several structural and 
functional alterations related to neuropsychological impair-
ments in patients with mood disorders have been documented 
via neuroimaging (9). In addition to gray matter changes such as 
atrophy in the prefrontal cortex (PFC), the cingular cortex with 
prominent changes in the left subgenual cingular cortex (39), the 
temporal cortex, and the basal ganglia (39), white matter dam-
age has also been documented (40). In particular, the effects of 
cortisol on brain structure has been suggested to be relevant in 
the etiology of MDD more generally and of cognitive impairment 
in depression in particular. Since pathological abnormalities of 
3Baune and Air The Cognition and Function Study – COFAMS
Frontiers in Psychiatry | www.frontiersin.org August 2016 | Volume 7 | Article 150
the hypothalamic-pituitary-adrenal axis (HPA) in conjunction 
with an increased excretion of cortisol in depression have been 
described, the abnormalities of the HPA axis following stress may 
lead, or at least contribute, to the structural changes such as those 
evident in the hippocampus. These findings are supported by 
numerous studies, which have established an association between 
duration of the mood disorder/numbers of episodes (41, 42) and 
early traumatization (43), and the degree of hippocampal damage. 
In addition, the effect of stress on the hippocampus appears to be 
modulated by genetic factors (44). It should also be considered 
that structural abnormalities can represent a vulnerability factor 
for the development of mood disorders and hypercortisolism 
(45). Overall, imaging studies show that neurocircuitry dysfunc-
tion appears to occur in the same pathways in depression and 
cognition (9), similarly to the involvement of monoamines, gluta-
mate, and gamma-aminobutyric acid (GABA) in both depression 
and cognition.
Additional neurobiological factors that affect both depres-
sion and cognition include neuroinflammatory and metabolic 
changes (46). Specifically, the role of inflammation is an impor-
tant biological mechanism of cognitive function. This suggestion 
rests on both the cytokine model of depression (47, 48) and on 
the the cytokine model of cognitive function that outline the role 
of cytokines (e.g., TNF-α, IL-6, and IL-1β) in regulating sickness 
behavior and neurobiological processes subserving cognition, i.e., 
synaptic plasticity, synaptic scaling, neurogenesis, neurotrans-
mission, and long-term potentiation/depression (LTP/LTD) that 
are relevant to cognitive function in depression (49). In a recent 
pilot investigation of CoFaMS, we reported the involvement of 
B lymphocyte proliferation and ribosomal S26 transcripts spe-
cifically in relation to cognitive dysfunction in remitted major 
depressive disorder (50). Other potential genomic biomarkers of 
cognitive dysfunction in depression, such as inflammatory and 
immune, among neurotransmitter and neurotrophic markers 
require further investigation (51).
Hence, the overall aim of the CoFaM Study is to investigate the 
long-term clinical course of cognitive dimensions in depression 
and its functional (psychosocial) correlates. In addition, the study 
aims to identify biological “genomic” correlates of these cogni-
tive dimensions of depression. By taking a prospective approach 
and by including a healthy control group, the study will increase 
the understanding of the cognitive dimensions of depression, 
its biological correlates, and its functional outcomes, etiology, 
pathophysiology, and state vs. trait characterization.
MEtHodS
objectives
To address the above overall aim, we created the Cognition and 
Mood Study (CoFaMS) with the key objective to investigate the 
clinical, functional, and biological correlates of cognitive dimen-
sions of depression by employing a prospective study design and 
including a healthy control group.
The key hypotheses and aims of the project are:
  Hypothesis 1: Participants with mood disorders have poorer 
neuropsychological function in the cognitive dimensions of 
cognitive function, emotion processing, and social cognition 
compared to healthy matched controls.
  Hypothesis 2: Participants with mood disorders have poorer 
quality of life and poorer psychosocial functional outcomes 
that will correlate with the level of impairment in cognitive 
dimensions of depression.
  Hypothesis 3: Participants with mood disorders show a 
biological genomic “signature” that relates to cognitive dimen-
sions of depression.
Study design and recruitment
The outlined study design commenced in April 2015 and 
includes baseline and follow-up assessments at 6-weeks and 
12-months post baseline. The design of the study is prospective 
in nature and includes a healthy control group. The natural-
istic recruitment of patients aged 18  years or above occurs 
in inpatient and outpatient units through research clinics of 
the Department of Psychiatry, University of Adelaide and the 
Eastern, Western, and Northern Mental Health Networks in 
Adelaide, South Australia. Recruitment may also include the 
general community through advertisement. Healthy controls 
are recruited from the same population background as the 
patients.
inclusion and Exclusion Criteria
The inclusion criterion is a current or previous diagnosis of a 
major depressive episode according to the DSM-IV-TR (52). 
Primary diagnosis of participants therefore included both uni-
polar and bipolar depressive disorders. Exclusion criteria were 
previous diagnosis or high screening score of a psychotic disorder, 
dementia, learning disorder, eating disorder or autistic spectrum 
disorder or medical conditions affecting the central nervous 
system (CNS) (e.g., multiple sclerosis, Parkinson’s disease, brain 
tumor). Healthy controls were required to have no previous or 
current psychiatric morbidity.
Ethics
The study was approved by the Human Research Ethics 
Committees at the University of Adelaide (approval number: 
H-160-2011) and the Royal Adelaide Hospital Human Research 
Ethics (approval number: 111230). Study participants were 
explained all study details in writing and in person before giving 
informed consent.
CliniCal, SElF-rEPort, and 
CoGnitiVE aSSESSMEntS
diagnostic interview
All participants are screened for mood symptoms using the 
MINI600 Neuropsychiatric Diagnostic Interview. All sections 
of the MINI600 are administered, including Major Depressive 
Episodes, Manic and Hypomanic Episodes, Psychotic Disorders 
and Mood Disorders with Psychotic features, Panic Disorder, 
Alcohol Abuse and Dependence, and Substance Abuse and 
Dependence. The MINI600 is a well-validated measure with psy-
chometrics showing good to excellent specificity and sensitivity 
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concordance to both the Structured Clinical Interview for the 
American Psychiatric Association Diagnostic criteria (SCID) 
and the Composite International Diagnostic Interview (ICD-10) 
(53,  54). The psychometric properties and the psychometric 
validation of the MINI have been published extensively (53, 54).
Symptom Severity
The Structured Interview Guide of the Hamilton Anxiety and 
Depression Scale (SIGH-AD) (55) is administered as it assists 
with establishing severity of symptoms. The SIGH–AD is a 
31-item structured interview that combines the Hamilton 
Depression Scale (HAM-D, 17 items) and the Hamilton Anxiety 
Scale (HAM-A, 14 items). Values over 15 represent clinically 
significant levels of anxiety or depression, respectively.
Psychiatric History
A psychiatric history checklist is administered to assess informa-
tion, such as age of onset of illness, number of lifetime episodes of 
mood disorders, number of hospitalizations, and family history 
of mental illness.
Functioning
The participants are administered a questionnaire assessing 
domains of activities in daily living, using the Functioning 
Assessment Short Test (FAST) (56, 57). The FAST scale consists 
of 24 items and has been developed for the clinical evaluation of 
the main difficulties in daily functioning presented by psychiat-
ric patients, particularly, bipolar disorder patients. It is easy to 
apply, requires only a short period of time for administration, 
and is available in several languages. The items are rated 0 (no 
impairment), 1 (mild impairment), 2 (moderate impairment), 
or 3 (severe impairment). The overall FAST scores range from 0 
to 72, where higher scores indicate greater disability, with scores 
above 11 indicating the presence of significant disability. The 
FAST derives individual scores for various domains of function, 
including a global score of functioning and the domains of 
autonomy, occupation, cognition, finances, relationship, and 
leisure. The time frame for evaluation of functioning is the 
last 14 days.
Work Productivity
A self-made employment questionnaire is administered to the 
participants. This questionnaire was developed to assess the 
impact of cognitive problems on employment status and work 
productivity in individuals suffering from mood disorders. The 
questionnaire is an interviewer-administered instrument. The 
studied time frame refers to the current employment status of the 
participant in the first section and their work productivity over 
the last 7 days in the second section. It is quick and easy to admin-
ister (on average it takes ~5 min) and provides a comprehensive 
assessment of the impact mood-related cognitive dysfunction has 
on occupational functioning.
General Functioning
Participants are rated on their symptom severity using the 
Clinical Global Impression Severity Scale (CGI-S) and the 
Global Assessment of Functioning (GAF). The Clinical Global 
Impression scale (CGI) is frequently used in clinical research 
because of its face validity and practicability. The GAF combines 
the evaluation of symptoms as well as relational, social, and 
occupational functioning on a single axis. The scale runs from 1 
to 100 and is divided into 10 equal parts providing defining char-
acteristics, both symptoms and functioning, for each 10-point 
interval. A low rating reflects worse symptoms and a poorer level 
of functioning, whereas a high rating reflects less symptoms and 
a better level of functioning.
treatment response to Psychotropic 
Medication
The Lifetime Psychotropic Treatment Response scale (LPTR) is 
a modified scale from the Lithium Lifetime Treatment Response 
scale (LLTR) (58). The LPTR scale covers treatment response to 
various types of psychotropic medication and hence replaces the 
LLTR. Criterion A is used to estimate response to antidepressant 
treatment, while Criterion B is used to establish whether there 
is a causal relationship between clinical improvement and the 
treatment. The scale is quick and easy to administer (on average it 
takes about 5 min) and gives an overall picture of the effectiveness 
of antidepressant medication.
assessments of additional Clinical 
Characteristics
Participants will complete a battery of self-report questionnaires 
using standardized scales designed to assess aspects of emotion 
processing, stress and maltreatment exposure, perceptions of 
stress, coping strategies, quality of life, general capacity to func-
tion, health service utilization, and health beliefs. All components 
of the self-report measure are derived from well validated and 
widely used measures that are available in the public domain. 
Self-report measures include the Positive and Negative Affect 
Schedule (PANAS) (59–64), Perceived Stress Scale (PSS) (65–68), 
Short Form Health Survey (SF-36) (69–75), the Childhood 
Trauma Questionnaire (CTQ) (76), the Center for Epidemiologic 
Depression Scale (CES-D) (77), the Functional Assessment of 
Cancer Therapy Cognition (FACT-Cog version 3) (78), and the 
Resilience Scale (79). The psychometric properties of these self-
report measures have been published widely.
Some participants that will be recruited to the study will have 
a history of, or are suffering from depression with peripartum 
onset. These participants, due to their role as mothers of babies 
and very young children, face specific requirements of daily 
functioning, which are not well captured in the functioning scales 
used otherwise in the study. To address this potential gap, female 
participants with young children aged 0–5 are given the following 
questionnaires.
The Parenting Scale
The Parenting Scale (80) is a 30-item self-report questionnaire 
that measures three dysfunctional discipline styles in parents: 
laxness (permissive discipline), over-reactivity (authoritarian 
discipline), and hostility (use of verbal or physical force). Each 
item requires the parent to rate the likelihood of using a particular 
discipline strategy in response to common child misbehaviors 
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using a 7-point Likert-type scale. Item scares are summed and 
then averaged to give a total score ranging from 1 to 7. The 
Parenting Scale has been found to be a valid and reliable tool 
with good test–retest reliability (r = 0.84) and is recommended as 
a tool for measuring parenting skill (81) and will be an important 
and relevant measure of functioning specifically in mothers of 
young children. On average this questionnaire takes 10 min.
The Parenting Tasks Checklist
The Parenting Tasks Checklist (82) consists of 28 items (self-
report) designed to assess task-specific self-efficacy in parents. 
Parents rate how confident they feel when they are dealing 
with difficult child behavior in common parenting situations. 
Confidence is rated on a scale from 0 (“certain I cannot do it”) 
to 10 (“certain I can do it”). Two dimensions are measured: 
behavioral self-efficacy (confidence in dealing with specific 
child behaviors) and setting self-efficacy (confidence in different 
settings). Both scales (each has 14 items) have been shown to 
have good internal consistency (82). The emphasis of this test on 
self-efficacy complements, the functional domains of parenting 
assessed by the Parenting Scale (see above), and further adds to 
the detailed functional characterization, specific to life situation, 
of participating mothers with young children.
The Edinburgh Postnatal Depression Scale
The Edinburgh Postnatal Depression Scale (EPDS) is a self-report 
10-item questionnaire that was developed to identify women who 
have post-partum depression (PPD). Generally, the EPDS (83) is 
used as the gold standard to determine the presence of PPD, and 
it has been used antenatally to identify women at risk for PPD. 
The measure takes ~5 min to complete.
Cognitive assessments
Participants are administered series of computer-based game-like 
activities using the Psychology Experiment Building Language 
(PEBL), designed to assess memory and learning, attention, and 
working memory, executive function, and social cognition. All 
tests have been psychometrically validated and are used extensively 
in cognitive function research. The paper–pencil tests include the 
Repeatable Battery for the Assessment of Neuropsychological 
Status (RBANS) (84), the computer-based tests are part of the 
PEBL Battery – The PEBL (85), and the social cognition assess-
ments are elements of the Wechsler Adult Intelligence Scale 
Advanced Clinical Solutions Package (WAIS-IV-ACS) (86, 87).
The Psychology Experiment Building Language
The PEBL is a free, open-source software system that allows 
researchers and clinicians to design, run, and share among 70 
behavioral tests (85). We chose this battery as it is computerized, 
is available on a range of platforms, is updated frequently, and 
offers a range of cognitive tests suitable for the purpose of our 
study. For the CoFaM study, we selected the following cognitive 
tests from the PEBL (88).
Tower of London Test
Tower of London Test (89) is a well-known test used in applied clini-
cal neuropsychology for the assessment of executive functioning 
specifically to detect deficits in planning, which may occur due to 
a variety of medical and neuropsychiatric conditions.
Wisconsin Card Sort Test
Wisconsin Card Sort Test (WCST) (90) is a neuropsychological 
test of “set-shifting,” i.e., the ability to display flexibility in the face 
of changing schedules of reinforcement. Successful completion of 
the test relies upon a number of intact cognitive functions includ-
ing attention, working memory, and visual processing.
Corsi Block Tapping Test
Corsi Block Tapping Test (91) assesses visuo-spatial short term 
working memory. It involves clicking on and copying a sequence 
of up to nine identical spatially separated blocks as they are dis-
played in a certain order. The sequence starts out simple, usually 
using two blocks, but becomes more complex until the subject’s 
performance suffers.
Stroop Test – Stroop – Color-Word Interference
The Stroop test is a neuropsychological measure assessing 
processing speed and attention administered by computer (92). 
This is the only test we are using to assess processing speed. The 
Stroop interference task, in particular, measures the ease with 
which a person can shift his or her perceptual set to conform 
to changing demands. The interference task consists of a series 
of color words, but the words themselves are colored in a dif-
ferent color ink than the color to which they refer. Participants 
are required to name the color of the word but not the word 
itself. Impaired attention/concentration is a common symptom 
in mood disorders. The administration of this test is about 
7–10 min.
Repeatable Battery for the Assessment of Neuropsychological 
Status
The RBANS is a brief, individually administered screening instru-
ment that aids in determining the neuropsychological status of 
adults aged 20–89 years (84). It has been used in a variety of clinical 
populations, including depression, dementia, and schizophrenia. 
The RBANS was developed for the dual process of identifying and 
characterizing abnormal cognitive decline in older adults and as 
a screening battery for younger patients. The RBANS gives scaled 
index scores for five cognitive domains: immediate memory, 
visuo-spatial/constructional, language, attention, and delayed 
memory. The RBANS has been demonstrated to have high reli-
ability, test–retest stability, inter-rater reliability, content validity, 
and construct validity and has been administered in various 
clinical populations, including schizophrenia, depression, and 
dementia among others (86, 87).
THINC-It Tool
The THINC-it tool has been developed in response to the need 
for a brief screening instrument for detecting cognitive deficits 
in patients with depression. It was designed to screen – not to 
diagnose – for objectively assessed cognitive function in depres-
sion by employing a variety of well-established cognitive tests 
(93). The tool contains tests of digit coding, choice reaction time, 
the one-back memory paradigm, and various versions of the Trail 
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Making Test Part B. In addition, measure of subjectively reported 
cognitive deficits – Perceived Deficit Questionnaire (PDQ) – has 
been added to the THINC-it assessment tool (94, 95).
Digit Coding
This is a measure of attention, perceptual speed, motor speed, 
visual scanning, and memory. The test requires the examinee to 
transcribe a unique geometric symbol with its corresponding 
number. The examinee is initially shown a key containing the 
numbers from 1 to 6. Under each number, there is a correspond-
ing geometric symbol. The participant is then shown a series of 
numbers on the screen and asked to match the number with the 
corresponding geometric symbol.
Choice Reaction Time
This test is used to assess psychomotor speed and choice reac-
tion time. In this test, participants are instructed to respond by 
pressing keys on the left or the right hand side of the keyboard 
corresponding to the direction to which an arrow on the screen 
is pointing.
N-Back
The N-Back test is measures executive control of the updating 
of information in working memory. The N-Back task is one in 
which the participant is presented a series of stimuli at a constant 
rate. The task of the participant is to map the currently presented 
stimulus on arrow keys of a keyboard to one they have recently 
seen in the stream (one position back).
Trail-Making Test B
Trail-Making Test B is a neuropsychological test of visual atten-
tion and task switching. Participants are instructed to connect a 
set of 18 dots as fast as possible while still maintaining accuracy. 
It can provide information about visual search speed, scanning, 
speed of processing, mental flexibility, as well as executive 
functioning.
Social Cognition
The WAIS ACS Social Cognition Test is an integrated test 
including facial affect, prosody, body language, and mental state 
interpretation. It has the advantage of a large normative sample 
of 800 subjects matched to the US census and has been validated 
with promising results against currently used facial affect rec-
ognition tasks in the setting of other psychiatric conditions. It 
comprised three subtests: affect naming, prosody-face matching, 
and prosody-pair matching. The subgroups each test a different 
aspect of social cognition (86, 87).
Blood Specimen
For later genomic biomarker analyses (e.g., genetic, gene expres-
sion, sequencing, proteomics, epigenomics, serum/plasma levels 
of biomarkers), peripheral blood will be taken at each time-point 
of assessment for deriving DNA, RNA, serum, and plasma. The 
storage of biomaterials is split between different refrigerators, 
all of which were monitored by a central alert system 24 h/day 
7 days/week.
Quality assurance and data Management
The primary goal of all quality assurance measures is to gener-
ate high quality data. The CoFaMS standard operations manual 
contains operating procedures for all CoFaMS interview and 
examination components. Prior to the beginning of CoFaMS-
Baseline, the members of the study team underwent an initial 
training with follow-up quality checks. Performance is closely 
monitored and routinely assessed. Data management has been 
carried out in parallel with data collection, based on standard-
ized and partly automated procedures for data processing and 
plausibility checking. Data backup routines are scheduled on a 
daily basis.
Biometric Concept and Statistical 
analyses
The primary endpoints of COFaMS are the presence and sever-
ity of deficits of the cognitive dimensions of depression namely 
cognitive function, emotion processing, and social cognition and 
also include psychosocial and general function, genomic mark-
ers, and serum/plasma levels of biomarkers. Secondary outcomes 
include change in cognitive dimensions and psychosocial func-
tion over time and genomic markers and serum/plasma levels of 
biomarkers in peripheral blood.
Depending on the outcome scale level (continuous vs. cat-
egorical) and time point of assessment (baseline vs. follow-up), 
the statistical methods comprise multivariable linear or logistic 
regression analyses, accounting for time-varying predictors and 
repeated outcome assessment. In addition, genomic marker 
analyses require specific software suitable for genetic analyses, 
gene expression analyses, network analyses, proteomics analyses, 
and other specialized analysis software packages.
diSCuSSion
Depression is a mental disorder that is characterized by a 
recurrent course of illness in many cases, by clinical and bio-
logical heterogeneity contributes largest to the burden of disease. 
Specifically, depression reduces psychosocial function and work 
productivity. Among the symptom clusters of depression, cogni-
tive dimensions are prominent and include emotion process-
ing, cognitive function, and social cognition. These cognitive 
dimensions as key features of depression appear to be relevant 
for psychosocial function and present as targets of psychologi-
cal treatment (e.g., cognitive-behavioral therapy). The CoFaM 
Study aims to improve the understanding of the clinical, func-
tional, and biological correlates of three cognitive dimensions of 
depression: emotion processing, cognitive function, and social 
cognition. Advances in the understanding of these cognitive 
dimensions are important to identify new treatment targets and 
to prevent decline in functional capacity. Recruitment of cases 
and controls of CoFaMS is ongoing. Study recruitment continues 
until December 2018.
First, the CoFaM Study is suited to characterize three major 
cognitive dimensions of depression with an emphasis on 
cognitive function, social cognition, and emotion processing 
in depressed participants compared to healthy controls. The 
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important trait-state characteristics of cognitive symptoms of 
depression will be addressed since this study includes patients 
with current, recurrent, and remitted depression cross-section-
ally and prospectively. In addition, the included assessment of 
psychiatric comorbidity, such as anxiety disorders, will enable us 
to account for the impact of psychiatric comorbidity on cogni-
tive dimensions of depression. A comparison to other mood 
disorders, such as bipolar disorder, extends this approach.
Second, the often observed psychosocial and functional 
decline and inability to recover after an acute episode of depres-
sion to premorbid functioning requires a better understanding 
of the mediators of functional decline. The CoFaM Study will 
address this key question by investigating the mediating role of 
the three cognitive dimensions in functional impairment decline 
in depression. A possible outcome of this study might be a better 
understanding of this crucial relationship, and the research might 
provide new leads into improving psychosocial functioning in 
the future.
Third, the biological correlates and genomic biomarker of 
depression specifically are lacking in the field. One of the reasons 
might be the heterogeneity of depression that inhibits a clearer 
correlation between symptoms of depression and biological 
correlates. By focusing on cognitive dimensions of depression, it 
is assumed that cognitive function might more closely correlate 
with biological markers (e.g., BDNF, inflammatory marker) 
than a global syndrome of depression consisting of a variety of 
symptoms clusters. The CoFaM Study allows for the study of the 
molecular underpinnings of cognitive dimensions by collecting 
extensively specimen for genetic, gene expression, epigenomic, 
sequencing, and serum/plasma analyses.
In conclusion, the CoFaM Study represents an innovative 
approach focusing on cognitive dimensions of depression and 
its functional and biological “genomic” correlates. The CoFaMS 
team welcomes collaborations with both national and interna-
tional researchers.
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